0000310568-16-000275.txt : 20160113 0000310568-16-000275.hdr.sgml : 20160113 20160113162141 ACCESSION NUMBER: 0000310568-16-000275 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160113 DATE AS OF CHANGE: 20160113 EFFECTIVENESS DATE: 20160113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MICROSEMI CORP CENTRAL INDEX KEY: 0000310568 STANDARD INDUSTRIAL CLASSIFICATION: SEMICONDUCTORS & RELATED DEVICES [3674] IRS NUMBER: 952110371 STATE OF INCORPORATION: DE FISCAL YEAR END: 1002 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 000-08866 FILM NUMBER: 161341014 BUSINESS ADDRESS: STREET 1: ONE ENTERPRISE CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: 949-380-6100 MAIL ADDRESS: STREET 1: ONE ENTERPRISE CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: MICROSEMICONDUCTOR CORP DATE OF NAME CHANGE: 19830323 DEFA14A 1 proxystatement2015-amendme.htm DEFA14A DEFA14A


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 SCHEDULE 14A
 Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. 1)
 
Filed by the Registrant x
Filed by a Party other than the Registrant o
 
 
 
 
Check the appropriate box:
o
Preliminary Proxy Statement
o
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o
Definitive Proxy Statement
 
x
Definitive Additional Materials
 
 
o
Soliciting Material Pursuant to §240.14a-12
 
 
 MICROSEMI CORPORATION
(Name of Registrant as Specified In Its Charter)
 (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 Payment of Filing Fee (Check the appropriate box):
x
No fee required.
o
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)    Title of each class of securities to which transaction applies:  
(2)    Aggregate number of securities to which transaction applies:       
(3)
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):      
(4)    Proposed maximum aggregate value of transaction:      
(5)
Total fee paid:      
o    Fee paid previously with preliminary materials.
o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.  
(1)
Amount Previously Paid:    
(2)
Form, Schedule or Registration Statement No.:     
(3)
Filing Party:     
(4)
Date Filed:     
 





On or about December 18, 2015, Microsemi Corporation (the “Company”) furnished or otherwise made available to stockholders its proxy statement (the “Proxy Statement”) describing the matters to be voted upon at the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) to be held at the Company’s corporate offices located at One Enterprise, Aliso Viejo, California at 10 a.m. on Tuesday, February 9, 2016. This supplement (this “Supplement”) provides some additional information for stockholders to consider with respect to Proposal No. 3 (Approval of Amendment to the 2008 Performance Incentive Plan) and should be read in conjunction with the Proxy Statement. This Supplement is first being furnished or otherwise made available to stockholders on or about January 13, 2016. All capitalized terms used but not defined in this Supplement have the meanings ascribed to them in the Proxy Statement.
The table included on page 59 of the Proxy Statement shows the total number of shares of the Company’s common stock that were subject to outstanding restricted stock and restricted stock unit awards granted under the 2008 Plan, that were subject to outstanding stock options granted under the 2008 Plan (with the weighted average exercise price and weighted average remaining life of those grants), and that were then available for new award grants under the 2008 Plan. The following table supplements this information by including information on awards that were then outstanding under the 1987 Plan, as well as for awards assumed by the Company pursuant to acquisitions, in each case as of September 27, 2015 and as of December 2, 2015.
 
September 27, 2015
 
December 2, 2015
 
Outstanding
 
Weighted Average Exercise Price
 
Weighted Average Remaining Life (Years)
 
Outstanding
 
Weighted Average Exercise Price
 
Weighted Average Remaining Life (Years)
Shares subject to outstanding restricted stock and restricted stock unit awards granted under the 2008 Plan and the 1987 Plan (excluding performance-based vesting awards) (1)
2,749,667

 
 
 
 
 
1,561,282

 
 
 
 
Shares subject to outstanding performance-based vesting restricted stock unit awards granted under the 2008 Plan and 1987 Plan (at the targeted level of performance; actual payment could range from 0% up to a maximum, not in excess of 270%, of the targeted level based on actual performance) (1)
669,928

 
 
 
 
 
587,871

 
 
 
 
Shares subject to outstanding stock options and stock appreciation rights granted under the 2008 Plan and 1987 Plan (2)
61,000

 
$
30.57

 
0.4

 
1,000

 
$
23.69

 
1.2

Shares subjected to outstanding restricted stock and restricted stock unit awards assumed by the Company pursuant to acquisitions (3)
280,471

 
 
 
 
 
250,320

 
 
 
 
Shares subject to outstanding stock options and stock appreciation rights assumed by the Company pursuant to acquisitions
639,607

 
$
18.55

 
4.3

 
607,245

 
$
18.61

 
4.3

Shares available for new award grants under the 2008 Plan (4)
11,743,580

 
 
 
 
 
12,120,131

 
 
 
 
(1)
There were no shares subject to outstanding restricted stock and restricted stock unit awards granted under the 1987 Plan (excluding performance-based vesting awards) or shares subject to outstanding performance-based vesting restricted stock unit awards granted under the 1987 Plan. As such the amounts reported in these rows reflect awards outstanding under the 2008 Plan.
(2)
Shares subject to outstanding stock options and stock appreciation rights granted under the 1987 Plan as of September 27, 2015 were 60,000 with a weighted average exercise price of $30.68 and a weighted average remaining life of 0.4 years. These awards were exercised in the period between September 27, 2015 and December 2, 2015.
(3)
There were no performance-based vesting awards assumed by the Company pursuant to acquisitions.
(4)
Shares available for new award granted grants under the 2008 Plan remain unchanged from previously reported amounts on the table on page 59 of the Proxy Statement and is presented here for the convenience of the reader.